OMS, 22 de octubre de
2015
Tabla de contenidos
Regulatory Matters
- Amantadine hydrochloride
- Asunaprevir and daclatasvir
- Azithromycin hydrate
- Canagliflozin
- Clozapine
- Deferasirox
- Fingolimod
- Hydroxyzine-containing medicines
- Infliximab
- Ingenol mebutate gel
- Laninamivir octanoate and zanamivir
- Memantine hydrochloride
- Nivolumab
- Panitumumab
- Pomalidomide
- Proton pump inhibitors
- Risperidone
- Sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sterile talc
- Treanda® Injection
Safety of medicines
- Bortezomib
- Brintellix® (vortioxetine) and Brilinta® (ticagrelor)
- DPP-4 Inhibitors for Type 2 Diabetes
- Eltrombopag
- Etanercept
- Gadolinium-based Contrast Agents for Magnetic Resonance Imaging (MRI)
- Pseudoephedrine and ephedrine
- Rivaroxaban
- Tramadol oral drops
Signal
- Dextromethorphan and serious neurological disorders in children
- Olanzapine and accidental drug intake by children
- Temozolomide and Oesophagitis
Feature
- WHO-UMC-HSA Inter-Regional Pharmacovigilance Training, Singapore, 30 September -2 October
- 2015
- The World Health Organization organizes an integrated vigilance workshop for Eastern Mediterranean regional countries in Rabat
- Building Pharmacovigilance in Member States of Central African Economic Monetary Community (CEMAC)
Disponible en
http://bit.ly/1RYJ2M2
